
Stryker (SYK) Stock Forecast & Price Target
Stryker (SYK) Analyst Ratings
Bulls say
Stryker is well positioned to sustain high-single-digit to low-double-digit organic sales growth because its MedSurg, Endoscopy, Medical, and Vascular franchises all showed healthy demand, with 9.1% organic MedSurg growth, $1.02 billion of Endoscopy revenue, and $60 million of Vascular outperformance. Its outlook is also strengthened by market leadership in orthopedic robotics and operating room equipment, plus a disciplined innovation pipeline that includes the 1888 platform, Neptune due in 1H27, and potential Vascular commercialization in 2027. Financially, the company is supporting growth with robust cash generation, a $1 billion 3Q buyback and new $3 billion authorization, while the $400 million CMR Surgical investment expands soft-tissue robotics without heavy upfront R&D risk.
Bears say
Stryker is facing a more cautious fundamental backdrop as 3Q revenue of $6.52 billion and adjusted EPS of $3.52 both missed expectations, while FY2026 organic growth guidance was cut to 6.5%-7.0% from 8.3%-9.3%. The main weakness is concentrated in orthopedics, where hips and knees were flat year over year and management cited a softer market growing about 2.5%, slower launch uptake, prior-authorization friction, and execution disruptions tied to cyberattack-related pressures and an SAP transition. Although margins held up with gross margin at 65.4% and operating margin at 26.2%, the combination of lower growth expectations, lingering vascular supply issues, and slower share gains suggests the business is no longer compounding as consistently as before.
This aggregate rating is based on analysts' research of Stryker and is not a guaranteed prediction by Public.com or investment advice.
Stryker (SYK) Analyst Forecast & Price Prediction
Start investing in Stryker (SYK)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Stryker (SYK) Forecast
Stryker (SYK) Analyst Forecast & Price Prediction
Start investing in Stryker (SYK)
Order type
Buy in
Order amount
Est. shares
0 shares